If You Invested in Cosmos Holdings Inc. (COSM)

Cosmos Health Inc. (NASDAQ: COSM) is described in its public disclosures as a diversified, vertically integrated global healthcare group. Incorporated in Nevada in 2009, the company operates across pharmaceuticals, nutraceuticals, medical products and healthcare services, combining manufacturing, distribution, research and development, and digital health activities.

Cosmos Health owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. These brands are positioned within the nutraceuticals and over-the-counter (OTC) space and are referenced in multiple company news releases and SEC filings as core to its product offering.

Through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), Cosmos Health manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices within the European Union. This GMP- and EMA-certified platform underpins the company’s contract manufacturing activities as well as production for its own brands.

Cosmos Health also operates GDP-compliant wholesale and distribution businesses. According to company news, it distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through subsidiaries in Greece and the United Kingdom. The company’s disclosures further note a global distribution platform with expansion efforts across Europe, Asia and North America, and offices and distribution centers in Thessaloniki and Athens in Greece, and in Harlow in the UK.

Business Segments and Vertically Integrated Model

Based on its public description and earlier industry classifications, Cosmos Health’s activities span several segments: wholesale pharmaceutical distribution, pharmaceutical manufacturing, nutraceuticals and pharmaceuticals, and other related operations. The company has highlighted that wholesale activities have historically been a significant contributor to revenue, while manufacturing and branded nutraceuticals support higher-margin growth.

The vertically integrated model referenced in recent news and research coverage includes:

• Pharmaceutical distribution through subsidiaries serving pharmacies and distributors.
• GMP-certified manufacturing at Cana Laboratories S.A. for pharmaceuticals and related products.
• Proprietary nutraceutical and pharmaceutical brands such as Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®.
• Contract manufacturing for third parties, as illustrated by agreements such as the PathMuscle manufacturing and supply agreement and other contract manufacturing arrangements mentioned in company communications.
• Digital health and telehealth services through the acquisition of ZipDoctor, Inc., a U.S.-based telehealth subscription platform.
• AI-enabled research and development via Cloudscreen, an AI-enabled drug repurposing and R&D platform used to support drug discovery and repurposing efforts.

Research, Development and AI-Enabled Innovation

Cosmos Health reports that it has established R&D partnerships targeting major health disorders such as obesity, diabetes and cancer. According to company news, its R&D activities include the development of novel patented nutraceuticals, specialized root extracts, proprietary complex generics and OTC products.

The company has disclosed specific development programs, including CCX0722 for obesity and weight management and additional repurposed compounds targeting conditions such as multiple sclerosis, allergies and oncology-related indications. These programs are supported by the Cloudscreen AI-enabled drug repurposing platform, which uses in silico screening and multimodal biochemical data to identify potential new therapeutic uses for existing compounds, with the stated goal of shortening development timelines and reducing discovery costs.

In the nutraceutical field, Cosmos Health has announced a nanotechnology R&D program to develop next-generation nutraceutical formulas. This program builds on proprietary know-how from the CCX Hydrogel platform and focuses on plant-based extract-loaded phytosomes designed to improve absorption, stability and bioactivity of phytochemicals for dietary supplements, using a solvent-free, sustainability-oriented process.

Telehealth and Digital Health Services

Cosmos Health has expanded into telehealth through the acquisition of ZipDoctor, Inc., a Texas-based telehealth subscription platform that provides direct-to-consumer access. The company’s news releases describe this as part of a broader strategy to add healthcare services alongside products, creating recurring engagement and complementing its physical product portfolio.

Digital Assets and Blockchain-Related Strategy

In addition to its core healthcare operations, Cosmos Health has disclosed a digital asset strategy supported by a financing facility of up to $300 million. Public announcements describe the use of this facility to acquire Ethereum (ETH) as a treasury asset and to diversify the company’s balance sheet.

The company has also announced a long-term strategic partnership with Prime Ledger LLC focused on digital asset treasury management and the tokenization of intellectual property assets. Under this partnership, Prime Ledger is expected to help establish a framework for managing digital asset treasury operations, design a token issuance platform for Cosmos Health’s IP, and integrate data infrastructure using Conduit Network to support financial reporting, regulatory compliance and performance analytics.

Geographic Footprint and Market Presence

Cosmos Health’s disclosures describe a global footprint anchored in Europe, with manufacturing and distribution operations in Greece and the UK, and expansion into the United States and other regions. The company has highlighted U.S. market entry for its Sky Premium Life brand and the acquisition of ZipDoctor in Texas, along with ongoing expansion throughout Europe, Asia and North America.

Within Europe, the company’s Cana Laboratories S.A. provides EU-based manufacturing, while distribution subsidiaries in Greece and the UK handle pharmaceuticals and parapharmaceuticals. Company communications also reference expansion of nutraceutical brands into regions such as the Gulf Cooperation Council (GCC) area through distribution agreements.

Capital Markets, Listing and Corporate Actions

Cosmos Health Inc. is incorporated in Nevada and its common stock, with a par value of $0.001 per share, trades on the Nasdaq Capital Market under the symbol COSM, as confirmed in multiple Form 8-K filings. The company has reported periods of non-compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), followed by subsequent regaining of compliance, as detailed in its October 2025 filings and press releases.

In 2025, Cosmos Health entered into a Securities Purchase Agreement to issue a series of 9% original issue discount senior secured convertible promissory notes with a maximum aggregate principal amount of $300 million. Related filings describe the use of proceeds, conversion mechanics, security arrangements, registration rights and voting agreements, as well as subsequent issuance of an initial $8 million note.

The company’s 2025 annual meeting materials and related Form 8-K filings describe stockholder approvals for an increase in authorized shares of common and preferred stock, authorization for a potential reverse stock split at the board’s discretion, approval of an equity incentive plan, and other governance matters. These filings also list the company’s directors elected at the annual meeting.

Business Model and Revenue Drivers

Based on the company’s own descriptions and prior classifications, Cosmos Health’s business model combines:

• Wholesale pharmaceutical and parapharmaceutical distribution to pharmacies and wholesale distributors.
• Pharmaceutical and nutraceutical manufacturing, including contract manufacturing for third parties and production of proprietary brands.
• Branded nutraceuticals and OTC products marketed under its own labels.
• Healthcare services through telehealth platforms.
• Research and development in pharmaceuticals and nutraceuticals, supported by AI-enabled platforms.
• Digital asset-related activities as part of a disclosed treasury and financing strategy.

Company news releases attribute recent revenue growth and margin expansion to contributions from contract manufacturing at Cana Laboratories, UK distribution through Decahedron, the CosmoFarm distribution business, and the global expansion of proprietary brands such as Sky Premium Life and C-Sept/C-Scrub.

Regulatory and Compliance Context

Cosmos Health’s manufacturing operations at Cana Laboratories S.A. are described as operating under European GMP and EMA certification, which frame the regulatory environment for its pharmaceutical and related production. Its listing on the Nasdaq Capital Market subjects it to U.S. securities regulations, ongoing reporting obligations and listing standards, including bid price requirements and corporate governance rules.

Through its SEC filings, the company provides periodic financial statements, disclosures about financing arrangements, governance changes, shareholder votes and other material events. These filings, together with press releases, form the primary public record of Cosmos Health’s operations, strategy and capital structure.

Position Within the Healthcare and Wholesale Trade Sector

Earlier industry classifications identify Cosmos Health within the Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers industry and the broader Wholesale Trade sector. Its own disclosures expand this view by emphasizing vertically integrated pharmaceutical and nutraceutical operations, digital health services and AI-enabled R&D, positioning the company across multiple parts of the healthcare value chain.